



Adagen[®] (pegademase bovine) – Product discontinuation

- On January 18, 2019, the [FDA announced](#) the discontinuation of Leadiant Biosciences' [Adagen \(pegademase bovine\)](#) 375 units/1.5 mL injection.
 - The discontinuation of the manufacture of Adagen is due to the permanent shortage of the active ingredient.
 - The discontinuation of the product is not due to product quality, safety, or efficacy concerns.
 - Based on the demand in mid-January 2019, the inventory is estimated to runout by late-March 2019.
- Adagen is approved for enzyme replacement therapy for adenosine deaminase deficiency in patients with severe combined immunodeficiency disease who are not suitable candidates for – or who have failed – bone marrow transplantation.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.